Just a short while after securing a CE Mark for its second generation device, Abbott has been granted FDA clearance for FreeStyle LibreLink, a companion mobile app for its 10 to 14-day CGM. The launch ...
Libre Assist 1 uses generative AI to predict how a food choice may affect a person's glucose levels. 2 It then offers actionable and personalized meal guidance 3 to support in-the-moment decisions.
Loop powered by mylife CamAPS FX becomes the first automated insulin delivery system in Canada compatible with two glucose monitoring systems for people living with type 1 diabetes ...
Abbott (NYSE:ABT) today unveiled a new feature within its FreeStyle Libre app for continuous glucose monitoring (CGM).
Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback